
The European Commission has approved the use of ocriplasmin for treating vitreomacular traction (VMT) in the European Union.
Ocriplasmin has been developed by ThromboGenics in collaboration with Novartis and will be sold under the brand name Jetrea. VMT is an age-related and progressive condition which could result in severe eye damage.
Advertisement
The drug has been approved for treating VMT when it is associated with a macular hole with a diameter of 400 µm or less.
ThromboGenics will be paid €45 million by Alcon, a subsidiary unit of Novartis, with a similar payment to be made with the first sale of the drug. Around 250,000-300,000 patients in Europe are reported to suffer from VMT with the current treatment involving a 'watchful process' until the patient is eligible for surgery.
Source: Medindia
Source: Medindia
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Drug News

Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.

The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.

The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.

Human apotransferrin injected to mice models suffering from intracerebral hemorrhage was found to mitigate the serious effects of stroke.

The reduction of these senescent osteoclasts, possibly through the utilization of current medications, could present a novel approach in managing lower back pain.